LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Home・Aandelen Lijst・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Open

SectorGezondheidszorg

1.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.05

Max

1.08

Belangrijke statistieken
By Trading Economics
Inkomsten	29M 3.3M
Verkoop	28M 29M
Winstmarge	11.266
Werknemers	103
EBITDA	31M 5.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+154.63% upside

Dividenden
By Dow Jones
Volgende Winsten	11 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-7M 400M
Vorige openingsprijs	1.08
Vorige sluitingsprijs	1.08

Nieuwssentiment

By Acuity

50%

173 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

0.6863 / 0.72 Steun & Weerstand

Lexicon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 nov 2024, 12:42 UTC

Belangrijke Marktbewegers

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Peer Vergelijking

Prijswijziging

Lexicon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

154.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.75 USD 154.63%

Hoogste 6 USD

Laagste 0.85 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lexicon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Lexicon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.6863 / 0.72Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

173 / 371 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.